Skip to search formSkip to main contentSkip to account menu

palbociclib

Known as: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one 
An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent… 
National Institutes of Health

Related topics

Related topics

16 relations

Broader (4)

Antineoplastic AgentsPiperazinesProtein Kinase InhibitorsPyridines
Cyclin-Dependent KinasesGene Expression RegulationKinase Inhibitors [MoA]NCIt Antineoplastic Agent Terminology

Narrower (1)

PD 0332991

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).
1057 Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are widely used for pts with HR+/HER2- MBC. The MONARCH-1 trial… 
Review
2019
Review
2019
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis.
2019
2019
A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10…
1007 Background: Endocrine treatment is preferred recommendation by clinical guidelines in premenopausal as well as… 
2018
2018
Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.
AIM CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in… 
Review
2018
Review
2018
Emerging Innovative Therapeutic Approaches Leveraging Cyclin‐Dependent Kinase Inhibitors to Treat Advanced Breast Cancer
Estrogen receptor‐positive (ER+) tumors represent the most common form of breast cancer. Although endocrine therapy (ET) results… 
2016
2016
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Palbociclib is a cyclin-dependent kinase (CDK) 4/CDK6 inhibitor approved for breast cancer that is estrogen receptor (ER… 
2016
2016
A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma
Background Single-agent ibrutinib confers a response rate of 77%, including a complete response (CR) rate of 19% in patients with… 
2016
2016
New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies
Although major advances in our understanding of the molecular underpinnings of hormone receptor–positive (HR+) breast cancer have… 
2016
2016
Plasma ESR 1 Mutations and the Treatment of Estrogen Receptor – Positive Advanced Breast Cancer
Purpose: ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact… 
2015
2015
Does CDKN2A loss predict palbociclib benefit?
Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)